Yoshimichi UEDA, Nobuyuki TOSHIKUNI, Takahiro MINATO, Yasuhiro MATSUE, Kaori KINOSHITA, Takashi SAITO, Mutsumi TSUCHISHIMA, Nobuhiko HAYASHI, Mikihiro TSUTSUMI

The combination of fatty liver and increased gamma-glutamyl transpeptidase levels as a risk factor for atherosclerotic plaque development in apparently healthy people

Background/aim: To elucidate how the combination of fatty liver and increased serum gamma-glutamyl transpeptidase (GGT) levelsinfluences atherosclerotic plaque development in apparently healthy people.Materials and methods: The study population included people who had received an annual health checkup for more than 7 years andhad no evidence of carotid plaque at baseline. We investigated the risk factors for carotid plaque occurrence using the Cox proportionalhazards model.Results: A total of 107 people (76 men and 31 women; median age, 49 years) were enrolled. At baseline, fatty liver and a serum GGTlevel ≥50 U/L were observed in 13 and 38 people, respectively. During a median follow-up period of 13.3 years, carotid plaques appearedin 34 people. Multivariate analysis revealed that the combination of fatty liver and a serum GGT level ≥50 U/L was the only significantrisk factor for carotid plaque occurrence (age- and sex-adjusted hazard ratio: 5.55; 95% confidence interval 1.70–18.14; P = 0.005).Conclusion: The combination of fatty liver and increased serum GGT levels raises the risk for atherosclerotic plaque development inapparently healthy people.

PDF

___

1. Insull W Jr. The pathology of atherosclerosis: plaque development and plaque responses to medical treatment. American Journal of Medicine 2009; 122 (1 Suppl): S3-s14. doi: 10.1016/j. amjmed.2008.10.013
2. Pucci A, Franzini M, Matteucci M, Ceragioli S, Marconi M et al. b-Gamma-glutamyltransferase activity in human vulnerable carotid plaques. Atherosclerosis 2014; 237 (1): 307-313. doi: 10.1016/j.atherosclerosis.2014.09.028
3. Belcastro E, Franzini M, Cianchetti S, Lorenzini E, Masotti S et al. Monocytes/macrophages activation contributes to b-gamma-glutamyltransferase accumulation inside atherosclerotic plaques. Journal of Translational Medicine 2015; 13: 325. doi: 10.1186/s12967-015-0687-6
4. Ndrepepa G, Colleran R, Kastrati A. Gamma-glutamyl transferase and the risk of atherosclerosis and coronary heart disease. Clinica Chimica Acta 2018; 476: 130-138. doi: 10.1016/j. cca.2017.11.026
5. Turgut O, Tandogan I. Gamma-glutamyltransferase to determine cardiovascular risk: shifting the paradigm forward. Journal of Atherosclerosis and Thrombosis 2011; 18 (3): 177-181.
6. Yang W, Kim CK, Kim DY, Jeong HG, Lee SH. Gamma-glutamyl transferase predicts future stroke: a Korean nationwide study. Annals of Neurology 2018; 83 (2): 375-386. doi: 10.1002/ ana.25158
7. Madan SA, John F, Pyrsopoulos N, Pitchumoni CS. Nonalcoholic fatty liver disease and carotid artery atherosclerosis in children and adults: a meta-analysis. European Journal of Gastroenterology & Hepatology 2015; 27 (11): 1237-1248. doi: 10.1097/meg.0000000000000429
8. Sinn DH, Cho SJ, Gu S, Seong D, Kang D et al. Persistent nonalcoholic fatty liver disease increases risk for carotid atherosclerosis. Gastroenterology 2016; 151 (3): 481-488.e481. doi: 10.1053/j.gastro.2016.06.001
9. Sinn DH, Kang D, Chang Y, Ryu S, Gu S et al. Non-alcoholic fatty liver disease and progression of coronary artery calcium score: a retrospective cohort study. Gut 2017; 66 (2): 323-329. doi: 10.1136/gutjnl-2016-311854
10. Targher G, Bertolini L, Rodella S, Lippi G, Franchini M et al. NASH predicts plasma inflammatory biomarkers independently of visceral fat in men. Obesity 2008; 16 (6): 1394-1399. doi: 10.1038/oby.2008.64
11. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. New England Journal of Medicine 2010; 363 (14): 1341-1350. doi: 10.1056/ NEJMra0912063
12. Toshikuni N, Asaji T, Nakanishi Y, Nagasawa S-y, Uenishi H et al. Elevated serum gamma-glutamyl transpeptidase levels and fatty liver strongly predict the presence of carotid plaque. Journal of Atherosclerosis and Thrombosis 2015; 22 (10): 1051- 1060. doi: 10.5551/jat.28274
13. Ogihara T, Kikuchi K, Matsuoka H, Fujita T, Higaki J et al. The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2009). Hypertension Research 2009; 32 (1): 3-107.
14. Touboul PJ, Hennerici MG, Meairs S, Adams H, Amarenco P et al. Mannheim carotid intima-media thickness consensus (2004-2006). An update on behalf of the advisory board of the 3rd and 4th Watching the Risk Symposium, 13th and 15th European Stroke Conferences, Mannheim, Germany, 2004, and Brussels, Belgium, 2006. Cerebrovascular Diseases 2007; 23 (1): 75-80. doi: 10.1159/000097034
15. Lee SS, Park SH. Radiologic evaluation of nonalcoholic fatty liver disease. World Journal of Gastroenterology 2014; 20 (23): 7392-7402. doi: 10.3748/wjg.v20.i23.7392
16. Polak JF, Pencina MJ, Pencina KM, O’Donnell CJ, Wolf PA et al. Carotid-wall intima-media thickness and cardiovascular events. New England Journal of Medicine 2011; 365 (3): 213- 221. doi: 10.1056/NEJMoa1012592
17. Lorenz MW, Polak JF, Kavousi M, Mathiesen EB, Volzke H et al. Carotid intima-media thickness progression to predict cardiovascular events in the general population (the PROG-IMT collaborative project): a meta-analysis of individual participant data. Lancet 2012; 379 (9831): 2053-2062. doi: 10.1016/S0140- 6736(12)60441-3
18. van den Oord SC, Sijbrands EJ, ten Kate GL, van Klaveren D, van Domburg RT et al. Carotid intima-media thickness for cardiovascular risk assessment: systematic review and metaanalysis. Atherosclerosis 2013; 228 (1): 1-11. doi: 10.1016/j. atherosclerosis.2013.01.025
19. Lacey B, Herrington WG, Preiss D, Lewington S, Armitage J. The role of emerging risk factors in cardiovascular outcomes. Current Atherosclerosis Reports 2017; 19 (6): 28. doi: 10.1007/ s11883-017-0661-2
20. Chitturi S, Farrell GC, Hashimoto E, Saibara T, Lau GK et al. Non-alcoholic fatty liver disease in the Asia-Pacific region: definitions and overview of proposed guidelines. Journal of Gastroenterology and Hepatology 2007; 22 (6): 778-787. doi: 10.1111/j.1440-1746.2007.05001.x
21. Breitling LP, Raum E, Muller H, Rothenbacher D, Brenner H. Synergism between smoking and alcohol consumption with respect to serum gamma-glutamyltransferase. Hepatology 2009; 49 (3): 802-808. doi: 10.1002/hep.22727
22. Tynjala J, Kangastupa P, Laatikainen T, Aalto M, Niemela O. Effect of age and gender on the relationship between alcohol consumption and serum GGT: time to recalibrate goals for normal ranges. Alcohol and Alcoholism 2012; 47 (5): 558-562. doi: 10.1093/alcalc/ags072
23. Alatalo PI, Koivisto HM, Hietala JP, Puukka KS, Bloigu R et al. Effect of moderate alcohol consumption on liver enzymes increases with increasing body mass index. American Journal of Clinical Nutrition 2008; 88 (4): 1097-1103.
24. Leite NC, Villela-Nogueira CA, Pannain VL, Bottino AC, Rezende GF et al. Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors. Liver International 2011; 31 (5): 700-706. doi: 10.1111/j.1478-3231.2011.02482.x
25. Fujiwara Y, Kuroda H, Abe T, Ishida K, Oguri T et al. The Bmode image-guided ultrasound attenuation parameter accurately detects hepatic steatosis in chronic liver disease. Ultrasound in Medicine & Biology 2018; 44 (11): 2223-2232. doi: 10.1016/j.ultrasmedbio.2018.06.017